Anti-CD122 antibody restores specific CD8
Hepatocellular carcinoma
immunotherapy
nonalcoholic steatohepatitis
Journal
Oncoimmunology
ISSN: 2162-402X
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
2023
2023
Historique:
entrez:
9
3
2023
pubmed:
10
3
2023
medline:
11
3
2023
Statut:
epublish
Résumé
Nonalcoholic steatohepatitis (NASH) can lead to hepatocellular carcinoma (HCC). Although immunotherapy is used as first-line treatment for advanced HCC, the impact of NASH on anticancer immunity is only partially characterized. We assessed the tumor-specific T cell immune response in the context of NASH. In a mouse model of NASH, we observed an expansion of the CD44
Identifiants
pubmed: 36891258
doi: 10.1080/2162402X.2023.2184991
pii: 2184991
pmc: PMC9988345
doi:
Substances chimiques
Programmed Cell Death 1 Receptor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2184991Informations de copyright
© 2023 The Author(s). Published with license by Taylor & Francis Group, LLC.
Déclaration de conflit d'intérêts
The authors report there are no competing interests to declare.
Références
Br J Surg. 2015 Sep;102(10):1250-7
pubmed: 26098966
J Hepatol. 2021 Oct;75(4):960-974
pubmed: 34256065
J Immunother Cancer. 2019 Feb 27;7(1):57
pubmed: 30813970
J Immunol. 2008 Jun 1;180(11):7431-42
pubmed: 18490743
Front Immunol. 2020 Sep 11;11:580968
pubmed: 33013934
Nature. 2021 Apr;592(7854):450-456
pubmed: 33762733
Hepatology. 2019 Feb;69(2):653-665
pubmed: 30102778
Exp Cell Res. 2016 Dec 10;349(2):291-301
pubmed: 27815020
Int Immunopharmacol. 2015 Jun;26(2):314-21
pubmed: 25891236
J Immunol. 2005 Jan 15;174(2):1055-62
pubmed: 15634930
Cell Mol Immunol. 2016 Nov;13(6):805-815
pubmed: 26412123
Gastroenterology. 2021 Jan;160(1):331-345.e6
pubmed: 33010248
J Hepatol. 2014 Aug;61(2):278-85
pubmed: 24713189
Oncotarget. 2017 Nov 24;8(65):109151-109160
pubmed: 29312597
JAMA Oncol. 2021 Jan 01;7(1):113-123
pubmed: 33090190
J Hepatol. 2021 Oct;75(4):865-878
pubmed: 33992698
Science. 2018 May 25;360(6391):
pubmed: 29798856
J Hepatol. 2022 Sep;77(3):748-760
pubmed: 35378172
Nature. 2021 Apr;592(7854):444-449
pubmed: 33762736
Gut. 2022 Apr 27;:
pubmed: 35477863
Hepatology. 2009 Feb;49(2):471-81
pubmed: 19105207
Hepatology. 2014 Mar;59(3):886-97
pubmed: 24115128
Am J Physiol Gastrointest Liver Physiol. 2020 Feb 1;318(2):G211-G224
pubmed: 31709830
Oncoimmunology. 2020 Oct 24;9(1):1829346
pubmed: 33150044
J Clin Invest. 2020 Sep 1;130(9):4679-4693
pubmed: 32497024
Gastroenterology. 2017 Sep;153(3):812-826
pubmed: 28624577
Gut. 2009 Jun;58(6):839-44
pubmed: 19174415
Nature. 2016 Mar 10;531(7593):253-7
pubmed: 26934227
JAMA Oncol. 2020 Apr 1;6(4):512-518
pubmed: 31876896
Cell Metab. 2018 Jul 03;28(1):104-117.e5
pubmed: 29861385
Oncoimmunology. 2016 Apr 22;5(6):e1160979
pubmed: 27471636
Nat Med. 2019 Jan;25(1):141-151
pubmed: 30420753
Nat Immunol. 2000 Oct;1(4):298-304
pubmed: 11017100
iScience. 2022 Feb 01;25(2):103847
pubmed: 35198900
J Clin Invest. 2018 Oct 1;128(10):4557-4572
pubmed: 30222140
Gastroenterology. 2017 Apr;152(5):1090-1099.e1
pubmed: 28088461
Nat Commun. 2013;4:2612
pubmed: 24113773